厄他培南静脉注射液治疗下呼吸道细菌性感染的有效性和安全性研究  

Study of effectivity and safety on ertapenem in the treatment of lower respiratory tract bacterial infection

作　　者：周宇麒 张天托 谢灿茂[2] 赵子文[3] 黄文杰[4] 于化鹏[5] 

机构地区：[1]山大学附属第一医院呼吸科,广州市510630 [2]中山大学附属第一医院呼吸科,广州市510089 [3]广州市第一人民医院呼吸科,510180 [4]广州军区广州总医院呼吸科,510010 [5]南方医科大学珠江医院呼吸科,广州市510280

出　　处：《实用医学杂志》2013年第1期110-113,共4页The Journal of Practical Medicine

摘　　要：目的:评价厄他培南1g注射液治疗下呼吸道细菌性感染的临床疗效与安全性。方法:采用多中心、前瞻性、开放性试验,入组124例,厄他培南注射液1g,1次/d静注,疗程7～14d。记录研究期间出现的任何不适症状与实验室异常结果,评估治疗结束时的临床和细菌学疗效及安全性。结果:厄他培南治疗社区获得性肺炎、慢性阻塞性肺疾病急性加重、支气管炎的有效率分别为75.5%(80/106)、81.3%(13/16)、100%(2/2),总有效率为76.6%(95/124),总细菌清除率为90.3%(28/31)。试验期间不良反应总发生率为2.4%(3/124)。结论:厄他培南治疗下呼吸道细菌性感染具有良好的疗效和安全性。Objective To evaluate the effectivity and safety of ertapenem in the treatment of lower respiratory tract bacterial infection.Methods A multicentre,prospective and open label clinical trail was conducted.One hundred and twenty-four cases were included and evaluated.The dosage of the drug was 1.0 g,once daily injection,the duration of treatment was 7～14 days.Any unexpected symptoms and abnormal laboratory results were recorded during the observing period.The clinical and bacterial curative effect and safety were evaluated at the end of treatment.Results The response rate was 75.5%(80/106),81.3%(13/16),100%(2/2) respectively in treating community acquired pneumonia,acute exacerbation of chronic obstructive pulmonary disease,bronchitis with ertapenem.The total response rate was 76.6%(95/124),the bacterial clearance rate was 90.3%(28/31).The total adverse effect occurrence rate was 2.4 %(3/124).Conclusion Ertapenem is an effective and safe drug in treating lower respiratory tract bacterial infection.

关 键 词：呼吸道感染 厄他培南 

分 类 号：R56[医药卫生—呼吸系统]